EntreMed, Inc. (ENMD) Announces FDA Acceptance of Company’s IND Application
EntreMed, Inc. (ENMD), a clinical-stage pharmaceutical company that develops medication for the treatment of cancer and inflammatory diseases, announced that the U.S. Food and Drug Administration accepted the company's Investigational New Drug Application for their Panzem(R) (2-Methoxyestradiol or 2ME2) product. This product is able to treat patients suffering from rheumatoid arthritis. Rheumatoid arthritis is a chronic inflammatory disease. This disease is often characterized by significant joint lining, aberrant angiogenesis, and progressive joint damage. EntreMed's Panzem drug consists of a small metabolite of 17beta-estradiol, able to counteract most side effects correlated with Rheumatoid Arthritis. Carolyn F. Sidor, M.D / M.B.A and…